INCYIncyte

Health care · Research Services · Nasdaq

Incyte is a global biopharmaceutical company engaged in the discovery, development and commercialization of proprietary therapeutics. 10-K, Item 1

Employees: 2,844
Headquarters: Wilmington, DE
CEO: William Meury
Next results: around Feb 9, 2027

Compare with peers → Embed

Dilution: new shares, stock pay and buybacks

prospectuses (S-3, 424B) of the last three years and the 10-K cash flow From EDGAR

Shares offered

Since Nov 11, 2023: no share offering; also 1 resale by holders.

Every offering filing →

Paid in stock

$249.3M

stock-based pay, year to Dec 31, 2025

Bought back

cash paid for its own shares, year to Dec 31, 2025

Diluted shares: 200.70M in the year to Dec 31, 2025 2025 -4.7%2024 -6.8%2023 +0.9%2022 +0.8%

Change in the diluted weighted average share count from the fiscal year before, stock splits taken out. Bars use one scale for stock pay and buybacks. Prospectuses are read from their cover page; preliminary ones are left out. Cash & buybacks, year by year → · How

Where the cash came from and where it went

Last year 3 years 5 years

FY2025, from the cash flow statement in the 10-K, added up.

Came from

Operating cash flow

NetCashProvidedByUsedInOperatingActivities, 0000879169-26-000010

$1.4B

Went to

Added to cash CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect, 0000879169-26-000010	$1.4B
Other, net investments bought and sold, other financing and investing lines, and exchange rates	$3.3M

Each number is a line of the cash flow statement as the company tagged it. "Other, net" is what those lines do not cover (investments bought and sold, other financing and investing lines, and exchange rates); Tickdelta does not estimate it.

Each CEO's years

The CEO of each fiscal year as named in the proxy's pay versus performance table, and what the 10-Ks show for those years. Facts, not a grade.

Mr. Meury

FY2025 · 1 year in the table

Operating cash flow: $1.4B
Buybacks: $0
Stock-based pay: $249.3M
Diluted shares since FY2024: -4.7%
Revenue since FY2024: +21%
CEO pay (reported): $38.5M

The proxy that names the CEO ↗

Mr. Hoppenot

FY2021 to FY2024 · 4 years in the table

Operating cash flow: $2.6B
Capital spending: $258.8M
Buybacks: $2.0B
Stock-based pay: $853.4M
Diluted shares since FY2020: -3.5%
Revenue since FY2020: +59%
CEO pay (reported): $65.2M

The proxy that names the CEO ↗

Buybacks, year to Dec 31, 2025

cash paid for its own shares

Paid in stock to employees

$249.3M

stock-based compensation

Share count, 1 year

-4.7%

fewer shares: each share owns more

Share count, 3 years

-10.4%

diluted average shares

Fiscal year to	Buybacks	Dividends	Stock pay	Shares issued for cash	Diluted shares
2025-12-31	$0	-	$249.3M	-	200.70M
2024-12-31	$2.0B	-	$266.1M	-	210.53M
2023-12-31	$0	-	$215.9M	-	225.93M
2022-12-31	$0	-	$188.4M	-	223.96M
2021-12-31	-	-	$183.0M	-	222.07M

From the XBRL of the 10-Ks (cash flow statement and diluted weighted average shares); each year as reported in the latest 10-K that includes it. Concepts: buybacks = PaymentsForRepurchaseOfCommonStock; sbc = ShareBasedCompensation; diluted_shares = WeightedAverageNumberOfDilutedSharesOutstanding.

Work on INCY in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/INCY/export.csv") into a cell.